"BRAF(V600E)-mediated MEK/ERK activation can upregulate MCL-1 by phosphorylation/stabilization to confer apoptosis resistance that can be reversed by MCL-1 antagonism combined with cobimetinib suggesting a novel therapeutic strategy against BRAF(V600E)-mutant CRCs"xsd:string